Please type a plus sign (+) Inside this box ->

PTC/SB/08A (10-96)
Approved for use through 10/31/99, OMB 0851-0031
and Trade/mark Offices U.S. DEPARTMENT OF COMMERCE

		Approved for use through	10/31/99. OMB 0851-0031
		Palant and Trademark Officer U.S. DEDAI	DEMENT OF COMMERCE
ICH	the Panawork Reduction Act of 1995, no persons are required to respond to a p	collection of information unless it contains a	valle OMB control number

Complete if Known " Substitute for form 1449A/PTO Application Number 10/088,250 INFORMATION DISCLOSURE Filing Date December 23, 2002 STATEMENT BY APPLICANT First Named Inventor FINK, et al. Group Art Unit 1626 (use as many sheets as necessary) Exeminer Name SHAMEEM, Golam M Sheet of **Altorney Docket Number USHMR2023 - US - PCT** 

				U.S. PATENT DOC	IMENTS	
Examiner Initiats	Cita No.1	U.S. Paten Number	Kind Code <sup>2</sup> (irsnown)	Name of Estables of Business	Date of Publication of Cled Document MM-DD-YYYY	Pages, Columns, Unes, Where Relevant Passages or Relevant Figures Addes
$\leq \chi$	•	5,258,672		WETTLAUFER, et, al.	10-26-1993	regules Appear
	•	5,578,319		BAKER, et. al.	11-19-1998	
	•	5,780,474		PEGLION, et al.	07-14-1998	
	<u> </u>	5,114,938		WETTLAUFER, et, al.	05-19-1992	
Ш	•	5,143,923		HRIB, et al.	09-01-1992	
	•	5,177,088		EFFLAND, et. al.	01-05-1993	
	•	5,180,834		WETTLAUFER, et, al.	01-19-1993	
$\square \square$		5,225,412		HRIB, et. al.	07-06-1993	
	•	5,328,920		EFFLAND, et. al.	07-12-1994	
	•	6,022,880		EFFLAND, et al.	02-08-2000	
I						,
				-		

				FOR	EIGN PATENT DOCUMEN	T\$		
Dominer	Cita		Foreign Patent Document  Office <sup>3</sup> Number <sup>4</sup> (# Innown)		Name of Patentee or	Date of Publication of	Pages, Columns, Lines,	$\top$
examinar exatini	No.1	Office			Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Te
$\sim$	٠	JP	10095770		MASANORI, et. al.	04-14-1998		Т
نال	٠	WO	92/06718		HOWARD, et al.	05-29-1992		Т
	•	WO	97/23482		SANNER, et. al.	07-03-1997		1
Va	•	WO	97/40027		LEYSEN, et. al.	10-30-1997		十
44	•	WO	99/40067		DEN HARTOG, et al.	08-12-1999		I
		-				<b> </b>		$\bot$
								╀
						<del>                                     </del>		+
			· · · · · · · · · · · · · · · · · · ·			<del>                                     </del>	<del></del>	+

Examiner	Date	101101
		1)/10/
Signature	Considered   /	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw tine through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the bro-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sertal number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>8</sup> Applicant is to place a check mark here if English tanguage Translation is attached.

Ptease type e plus sign (+) inside this box ->

PTO/SB/088 (10-98)
Approved for use Unough 10/31/89. ONB 0551-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

er the Paper	vork Reduction A	cl of 1995	. no persons are required to re	spond to a collection of informeth	on unless it contains a valid QMB control number.		
	a for form 14498		•	Complete if Known			
MICO	DIATI	<b>311</b> B	IOOL OOLIDE	Application Number	10/088,250		
			ISCLOSURE	Filing Date	December 23, 2002		
STA	TEMENT	<b>IBY</b>	APPLICANT	First Named Inventor	FINK, et al.		
		. – •		Group Art Unit	1626		
	(use as mai	y sheel	s as necessary)	Examiner Name	SHAMEEM, Golam M		
Sheet	2	of	2	Altomay Docket Number	USHMR2023 - US - PCT		

DOTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS  Examiner Initials*  Cite No.*  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the lettin (book, magazine, journal, surial, symposium, catalog, etc.), data, page (s), volume-lasue number(e), publisher, city and/or country where published.					
,	*	KONGSAMUT, S., et. al., lioperidone Binding to Human and Rat Dopamine and 5-HT Receptors, Database Chemises entiries Chemical Abstracts Service, Columbus, Offic, US fethawad from STN Satabase Accession No. 126:70003 XP002154329 * Eur. J. Pharmacol. (1998) Vol.317, (2/3)			
		-			
-					

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Cruel information Officer, Patent and Trademark Office, Washington, DC 20231.

OO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PAGE 7/22 \* RCVD AT 11/29/2005 1:49:32 PM [Eastern Standard Time] \* SVR:USPTO-EFXRF-6/33 \* DNIS:2738300 \* CSID:908 231 2626 \* DURATION (mm-ss):05-42

Signature

of Missing neperence - has

Considered

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →	lease	type	a plus	sign (+)	inside	this	box	$\rightarrow$	V
---	-------	------	--------	----------	--------	------	-----	---------------	---

Please type a plus sign (+) Inside this box PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	5
-------	---	----	---

Complete if Known						
Application Number	10/088,250					
Filing Date	12-23-2002					
. First Named Inventor	FINK, et. al.					
Group Art Unit	1626					
Examiner Name	SHAMEEM, Golam M.	Ξ				
Attorney Docket Number	USHMR2023 - US - PCT					

				U.S. PATENT DOCL	IMENTS	, ·
Examiner Initials*	Cite No.1	Number .	cument and Code <sup>2</sup> Il known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
2	•	4,075,227		JONES, et. al.	02-21-1978	
7	*	4,085,114		ADACHI, et. al.	04-18-1978	
	•	4,355,037		STRUPCZEWSKI, et. al.	10-19-1982	
	•	4,408,053		STRUPCZEWSKI, et. al.	10-04-1983	
	•	4,408,054		STRUPCZEWSKI, et. al.	10-04-1983	
	•	4,427,691		SHUTSKE, et. al.	01-24-1984	
	•	4,452,804		SHUTSKE, et. al.	06-06-1984	
	•	4,469,869		STRUPCZEWSKI, et. al.	09-04-1984	
	•	4,504,669		SHUTSKE, et. al.	03-12-1985	
	•	4,528,376		STRUPCZEWSKI, et. al.	07-09-1985	
	*	4,644,064		SHUTSKE, et. al.	02-17-1987	
	•	4,728,651		ONG, et. al.	03-01-1988	
	•	4,769,472		ONG, et. al.	09-06-1988	
	. *	5,254,595		GUZZI, et. al.	10-19-1993	·
	•	5,321,037		NAGANO, et. al.	06-14-1994	
	*	5,340,833		BRIDGES, et. al.	08-23-1994	
	٠	5,593,994		BATT, et. al.	01-14-1997	
	/ •	5,696,113	$\Box$	PALERMO, et. al.	12-09-1997	
	*	5,843,940		CULLINAN, et. al.	12-01-1998	
21	•	5,856,503		AEBI, et. al.	01-05-1999	

				FOR	EIGN PATENT DOCUMENT	rs		
Examiner Initials	Cite No.1	Office	Foreign Patent Do Number4	Cument Kind Code <sup>s</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	<b>T6</b>
61	•	EP	0058977		SHUTSKE, et al.	09-01-1982		
. 1	•	EP	0221414		ONG, et. al.	05-13-1987		
	•	EP	0729955		CULLINAN, et. al.	09-04-1996		
1/	٠	wo	01/19833		FINK, et. al.	03-22-2001		
$\mathbf{Y}_{\mathbf{a}}$	•	wo	97/28115		ADAMS, et. al.	08-07-1997		Т
4	•	GB	1,269,776		SMITH, et. al.	04-06-1972		$\bot$
		1				<del> </del>		╁╌
								T

**Date** Examiner Considered Signature

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a	plus sign (+)	inside this box	<b>→</b>	V

PTO/SB/08A (10-95)
Approved for use through 10/31/99, OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 5

Complete if Known					
Application Number	10/088,250				
Filing Date	12-23-2002				
First Named Inventor	FINK, et. al.				
Group Art Unit	1626				
Examiner Name	SHAMEEM, Golam M.				
Attorney Docket Number	USHMR2023 - US - PCT				

				U.S. PATENT DOCU	MENTS	
Examiner Initials	Cite No.1	Number .	ment d Code <sup>2</sup> mown)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	٠	5,932,586		BATT, et. al	08-03-1999	
,	٠	5,225,414		HENNING, et. al.	07-06-1993	
	•	5,852,022		PALERMO, et. al.	12-28-1998	
	•	5,965,554		PALERMO, et. al.	10-12-1999	
	•	6,103,724		LASZLOVSZKY, et. al.	08-15-2000	
W	•	6,121,293		CULLINAN, et. al.	09-19-2000	
	•	6,008,348		PALERMO, et. al.	12-28-1999	
					T.	
						•
					1	
				1		

				FORE	IGN PATENT DOCUMENT	rs		-
Examiner	Cite		oreign Patent Do	cument	Name of Patentee or	Date of Publication of	Pages, Columns, Lines,.	Ī
Initials	No.1	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (If known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Té
							_	
		<u> </u>						
						ļ		
		<b> </b>  _				1		
								<b>↓</b>
		$\vdash$		$\longrightarrow$	<del></del>			↓
								1

			/		
Examiner Signature	M	A/A	men	Date Considered	1126108

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not/in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please	type	a plus	sian	(+)	inside	this	box	-	
	.,,		- 3	٠,				-	

3

of

5

USHMR2023 - US - PCT

PTO/SB/08B (10-96)

Approved for use through 10/31/99, OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449B/PTO **Application Number** 10/088,250 INFORMATION DISCLOSURE Filing Date 12-23-2002 STATEMENT BY APPLICANT **First Named Inventor** FINK, et. al. **Group Art Unit** 1626 SHAMEEM, Golam M. (use as many sheets as necessary) **Examiner Name** 

**Attorney Docket Number** 

		locked many of the orthogon CARITAL ETTERNAL CO.	
Examiner nitials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	1
	*	ASGHARI, V., et. al., Dopamine D4 Receptor Repeat: Analysis of Different Native and Mutant Forms of the Human and Rat Genes, Molecular Pharmacology Vol. 46, pp. 364-373 (1994)	
	*	BASSITT, D.P., et. al., Clozapine Efficacy in Tardive Dyskinesia in Schizophrenic Patients, European Archives of Pyschiatry and Clinical Neuroscience Vol.248, pp. 209-211 (1998)	
	*	BENJAMIN, J., et. al., Population and Familial Association between the D4 Dopamine Receptor gene and Measures of Novelty Seeking, Nature Genetics Vol. 12, pp. 81-84 (1998)	
	*	BRYCE, M., et. al., Synthesis and Cyclic Voltammetric Behaviour of Some 3-Substituted Thiophenes and Pyrroles: Precursors for the Prepretion of Conducting Polymers, Synthetic Metal, Vol. 26, (1988) pp. 153–168.	
	*	CORBETT, R., et. al., Iloperidone: Preclinical Profile and Early Clinical Evaluation, CNS Drug Review Vol.3, No. 2, pp. 120-147 (1997)	
	*	CRENSHAW, R.R., et. al., Potential Antifertility Agents, 1. Substituted Diarl Derivatives of Benzo[b]thiophenes, Benzo[b]furans, 1H-2-Benzothlapyrans, and 2H-1-Benzothlapyrans1, Journal of Medicinal Chemistry, Vol. 14, No.12, (1971) pp. 1185-1190	
	*	CRUZ. C., et. al., Increased Prevalence of the Seven-Repeat Variant of the Dopamine D4 Receptor Gene in Patients with Obsessive-Compulsive Disorder with Tics, Neuroscience Letters Vol. 231, pp. 1-4, (1997)	
	*	EBSTEIN, R.E., et. al., Dopamine D4 Receptor (D4DR) exon III Polymorphism Associated with the Human Personality Traft of Novelty Seeking, Nature Genetics Vol. 12, (1996) pp. 78-89	_
	*	ELWORTHY, T. R., et. al., N-Arylpiperazinyl-N-Propylamino Derivatives of Heteroaryl Amides as Functional Uroseiective a1-Adrenoceptor Antagonists, Indian Journal of Chemistry — part B Organic Including Medicinal Vol. 40, pp.2674-2687, (1997)	
	*	ERENBERG, G., et.al., Gilas De La Tourette's Syndrome: Effects of Stimulant Drugs, Neurology Vol.35, No. 35, pp.1346-1348, (1985)	

Examiner Signature	as	Date Considered	112/06
-----------------------	----	--------------------	--------

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Reberence

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

			-	
Please type a	nius sian /+	) inside this how	[	
measo type o	brog order (	) inside this box	7	v

Rlease type a plus sign (+) inside this box Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449B/PTO **Application Number** 10/088,250 INFORMATION DISCLOSURE Filing Date 12-23-2002 STATEMENT BY APPLICANT **First Named Inventor** FINK, et. al. Group Art Unit 1626 (use as many sheets as necessary) **Examiner Name** SHAMEEM, Golam M. of 4 Attorney Docket Number USHMR2023 - US - PCT

		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	_
Examiner Initials	Cite No.1	Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Ţ
	*	FACTOR, S.A., et. al., The Emerging Role of Clozapine in the Treatment of Movement Disorders, Movement Disorders, Movement Disorders Vol. 12, No.4 (1997) pp. 483-496	<u> </u>
	*	FELDPAUSCH, D.L., et. al., The Role of Dopamine D4 Receptor in the Induction of Behavioral Sensitization to Amphetamine and Accompanying Biochemical and Molecular Adaptations, Journal of Pharmacology and Experimental Therapeutics Vol. 266, pp.497-508 (1998)	
	*	FRIEDMAN, J.H., et. al., Substituting Clozapine for Olanzapine in Psychiatrically Stable Parkinson's Disease Patients: Results of an Open Label for Pilot Study, Clinical Neuropharmacology, Vol. 21, No. 5 pp. 285-288 (1998)	_
	*	GRICE, D.E., et. al., Linkage Disequilibrium between an Allele at the Dopamine D4 Receptor Locus and Tourette Syndrome, by the Transmission-Disequilibrium Test, American Journal of Human Genetics Vol.59, pp.644-652 (1996)	-
:	*	HELSLEY, G.C., et. al., Piperidyalkylindoles. 1. Hypotensive Activity of 3-[2-(Phenoxypiperidyl)ethyl]Indoles, Journal of Medicinal Chemistry, (1978), Vol.21, No.3 pp. 309-312	
	*	LAHOSTE, G., et. al., Dopamine D4 Receptor Gene Polymorphism is Associated with Attention Deficit Hyperactivity Disorder, Molecular Psychiatry Vol. 1, pp. 121-124 (1996)	
<del></del>	*	LAHTI, R.A., et. al., Direct Determination of Dopamine D4 Receptors in Normal and Schizophrenic Postmortem Brain Tissue: A [3H]NGD 04-1 Study, Molecular Psychiatry Vol. 3, pp. 528-533 (1998)	
	*	MAGDO, I., et. al., 3D quantitative structure-activity relationship (CoMFA) study of heterocyclic arylpiperazine derivatives with 5-HT1A activity. Database Chemabs 'Online! Chemical Abstracts Service, Columbus, Ohio, US	<u> </u>
	*	RICKETTS, H., et. al., Association of Long Variants of the Dopamine D4 Receptor Exon 3 Repeat  Polymorphism with Parkinson's Disease, Clinical Genetics Vol. 34, pp. 33-38 (1998)	
	*	RUBINSTEIN, M., et. al., Mice Lacking Dopamine D4 Receptors are Supersitive to Ethanol, Cocaine, and Methamphetamine, Cell, Vol.90, pp. 991-1001 (1997)	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a	plus sign (+) i	Inside this box	→.	1

5

Sheet

PTC/SB/08B (10-96)

Approved for use through 10/31/99, OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)

5

Complete if Known					
Application Number	10/088,250				
Filing Date	12-23-2002				
First Named Inventor	FINK, et. al.				
Group Art Unit	1626				
Examiner Name	SHAMEEM, Golam M.				
Attorney Docket Number	USHMR2023 - US - PCT				

		Include name of the outher (in CADITAL LETTEDS) title of the added to be a series to the	
examiner nitials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	1
	*	SALL, D., et. al., Dibasic Benzo[b]thiophene Derivatives as a Novel Clace of Active Site-Directed Thrombin Inhibitors. 1. Determination of the Serine Protease Selectivity, Structure - Activity Relationships, and Binding Orientation, Journal of Medicinal Chemistry Vol.40, No. 22, (1997) pp. 3489 - 3493	6
•	*	SCHODER; J.; et. al., D2 Dopamine Receptor Up-Regulation, Treatment Response, Neurological Soft Signs, and Extrapyramidal Side Effects in Schizophrenia: A Follow-Up Study with 1231-lodobenzamide Single Photon Emission Compouted Tomography in the Drug Naive State and after Neuroleptic Treatment, Society of Biological Psychiatry Vol.43, pp.660-665, (1998)	
	*	SEEMAN, P., et. al., <u>Atypical Neuroleptics Have Low Affinity for Dopamine D2 Receptors or Are Selectivefor D4 Receptors</u> , <u>Neuropoychoppharmacology Vol.16</u> , Iss. 2, pp. 92-135 (1997)	
	*	SEEMAN, P., et. al., Schizophrenia: Eleveation of dopamine D4-like sites, using [3H]Nemonapride and [125I]Epidepride, European Journal of Pharmacology Vol.286 (1995) R3-R5	
	*	SHIELDS, P.G., et. al., Dopamine D4 Receptors and the Risk of Cigarette Smoke in African-Americans and Gaucasions1, Cancer Epidemiology, Biomarkers & Prevention Vol. 7, pp.453-458 (1998)	
	*	VAN TOL, H.M., et. al., Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine, Letters to Nature, Vol. 350, 1991, pp 610-614	
	*	VAN TOL, H.M., et. al., The Dopamine D4 Receptor: A Novel Site for Antipsychotic Action , Clinical Neuropharmacology Vol. 18, No. 1 pp. 5143-5153 (1995)	
	*	VANTOL, H.M., et. al., Mutiple Departine O4 Receptor Variants in the Human Population , Nature Vol. 358 - 9 (1992) - pp.149 -152	
	*	ZHU, J., et. al., Synthesis of 2-(4-Halogenobenzyl)-3-Arylbenzo(b]-Thiophenes and a 2 (4-Fluorobenzyl)-3-Arylbenzo[b]-Selenophene as Selective Ligands for Antiestrogen-Bluding Sites	

Examiner Signature	Date Considered	112/06
--------------------	--------------------	--------

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.